Journals / Ulusal Romatoloji Dergisi / 2020 / Cilt: 12 - Sayı: 2

Mortality in rheumatoid arthritis patients

Romatoid artrit hastalarında mortalite

Pages
57–63
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, our aim is to define the changes in the mortality rates over time and to provide current data on mortality rates and causes

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease characterized by chronic inflammation, increased comorbidities and elevated mortality risk.
📊
Key Findings & Data:Despite the fact that mortality rates are still high compared to general population, literature shows a decreased trend of mortality in RA.
💡
Conclusion & Impact:In this review, our aim is to define the changes in the mortality rates over time and to provide current data on mortality rates and causes
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease characterized by chronic inflammation, increased comorbidities and elevated mortality risk. High mortality in RA is widely studied but not fully clarified. Despite the fact that mortality rates are still high compared to general population, literature shows a decreased trend of mortality in RA. New treatment modalities might be the reason for decreased mortality rates. However, underestimated factors, such as low-grade inflammation, comorbidities, and immunologic or genetic factors, are the explanation to decreased survival rates compared to general population. The most common reasons of mortality are still the same as cardiovascular incidents, infections, malignancies and respiratory system problems. However, there is an ongoing need for further studies in long-term to see the effects of current improvements on mortality of RA. In this review, our aim is to define the changes in the mortality rates over time and to provide current data on mortality rates and causes

Özet

Romatoid artrit (RA), kronik sistemik enflamasyon, artmış morbidite ve mortalite riski ile karakterize, sistemik otoimmün bir hastalıktır. RA’da artmış mortalite yaygın olarak araştırılmış ancak tam olarak açıklanamamıştır. Yapılan çalışmalar RA hastalarında mortalite oranlarında azalma eğilimini göstermekle birlikte oranlar genel popülasyona göre yüksektir. Ölüm oranlarında iyileşme hastalığın yönetiminde ortaya çıkan yeni gelişmelerin sonucu olabilir. Ancak genel popülasyona göre düşük seyreden yaşam oranlarının nedeni çoğu zaman göz ardı edilen düşük seviyede enflamasyon, komorbiditeler, immünolojik ve genetik faktörlerdir. En sık ölüm nedenleri halen kardiyovasküler olaylar, enfeksiyonlar, maligniteler ve solunum sistemi ile ilişkili olaylar olup güncel gelişmelerin mortalite üzerine net etkisini görmek için uzun vadede yeni çalışmalara ihtiyaç vardır. Bu derlemede amacımız, RA ilişkili mortalitenin zaman içerisinde değişimini, güncel mortalite oranlarını ve mortalite nedenlerini vurgulamaktır.

🔖

Cite This Article

AYAN, G., HAMURYUDAN, V. (2022). Mortality in rheumatoid arthritis patients. Ulusal Romatoloji Dergisi, Cilt: 12 - Sayı: 2, 57–63. https://ajindex.com/articles/643905

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4:S265-72
  2. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108
  3. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018;4:18001
  4. Myasoedova E, Davis JM, 3rd, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010;12:379-85
  5. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7
  6. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004;33:221-7
  7. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol 1984;11:158-61
  8. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445-51
  9. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706-14
  10. Mutru O, Laakso M, Isomaki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985;290:1797-9
  11. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995;13:149-53
  12. Provan SA, Lillegraven S, Sexton J, et al. Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study. Rheumatology (Oxford) 2019;59:505-12
  13. Wallberg-Jonsson S, Johansson H, Ohman ML, RantapaaDahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71
  14. Corbett M, Dalton S, Young A, Silman A, Shipley M. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993;32:717-23
  15. Erhardt CC, Mumford PA, Venable